| Meta-analysis summary statistics for associations meeting genome-wide significance | |||||||
|---|---|---|---|---|---|---|---|
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs7061710 | X-11786--methylcysteine | C/G | 2773 | 0.23 | 0.045 (0.006) | 7.52·10-14 | show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations | |
|---|---|
| SNP | rs7061710 |
| Chromosomal location | Chr1: 169,347,239 (1q24.3) |
| Gene (distance) | FMO3 (0) |
| Predicted causal gene | FMO3 |
| Gene/protein classification | metabolic enzyme |
| Metabolite (Pathway) | X-11786--methylcysteine (Cysteine, methionine, SAM, taurine metabolism; Amino acid) |
| Biochemical locus-metabolite relationship | FMO3 can act on S-allyl-cysteine [18775983]. X-11786 was idenfied as methylcysteine and is a possible substrate of FMO3. |
| eQTL associations | FMO3 (F), FMO3 (S), FMO2 (F), FMO2 (S) † |
† F = adipose tissue; S = skin cells; L = lymphoblastoid cells; H = liver cells;
| Medical information | |
|---|---|
| Complex trait associations | - |
| Known metabolite associations | - |
| Inborn error of metabolism | - |
| Pharmacological information | |
|---|---|
| ChEMBL ID | - |
| Drug information | Substrate: chlorpromazine, trimethylamine, cimetidine |
| Locus information for top associated metabolite | |
|---|---|
HapMap2 imputation![]() | 1KGP imputation![]() |








